Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER1 | P34995 | 1/20 | 0.38 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.38 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.38 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 8/20 | 0.38 |
| ▸ | FFAR4 | Q5NUL3 | 8/20 | 0.38 |
| ▸ | PPARA | Q07869 | 2/20 | 0.36 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.36 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.36 |
| ▸ | MLNR | O43193 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1797650 | 1.00 | PTGER1 (0.38) | PTGER1PTGER4PTGER3PTGER2FFAR1 | |
| SCHEMBL1797654 | 0.79 | LPAR1 (0.43) | PTGER1PTGER4PTGER3PTGER2FFAR1 | |
| SCHEMBL1799801 | 0.76 | HDAC3 (0.40) | PPARA | |
| SCHEMBL1798511 | 0.76 | MLNR (0.43) | LTB4R2LPAR1MLNR | |
| SCHEMBL22327659 | 0.75 | L3MBTL1 (0.43) | SLC6A2SLC6A4SLC6A3LPAR1 | |
| SCHEMBL1799804 | 0.73 | HDAC1 (0.45) | PPARA | |
| SCHEMBL1801153 | 0.73 | HDAC1 (0.47) | PPARA | |
| SCHEMBL20741092 | 0.72 | DAGLA (0.41) | PPARA | |
| SCHEMBL20741091 | 0.72 | DAGLA (0.41) | PPARA | |
| SCHEMBL1926667 | 0.72 | KMT2A (0.43) | PPARASLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7951954-B2 | Bezothiazol derivatives as Beta2 adrenoreceptor agonists | ASTRAZENECA AB (SE) | 2011-05-31 | — | — | US | disclosed |
| US-20090062259-A1 | Bezothiazol Derivatives as Beta2 Adrenoreceptor Agonists | ASTRAZENECA AB (SE) | 2009-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062259-A1 | Bezothiazol Derivatives as Beta2 Adrenoreceptor Agonists | ADRB2, ADRB1, ADRB3 | PTGER1 204/4885PTGER4 317/4885PTGER3 333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.